Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases

• Published in: Jornal brasileiro de pneumologia Vol. 47; no. 3; p. e20200096
• Main Authors: Torres, Pedro Paulo Teixeira E Silva, Rabahi, Marcelo Fouad, Moreira, Maria Auxiliadora do Carmo, Escuissato, Dante Luiz, Meirelles, Gustavo de Souza Portes, Marchiori, Edson
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Pneumologia e Tisiologia 01.01.2021
• Subjects: Diagnostic imaging; Disease Progression; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis - diagnostic imaging; Lung - diagnostic imaging; Lung Diseases, Interstitial - diagnostic imaging; Pulmonary fibrosis; RESPIRATORY SYSTEM; Review; Tomography, X-ray computed; Fibrose pulmonar; Diagnostic imaging; Pulmonary fibrosis; Tomography, X-ray computed; Diagnóstico por imagem; Tomografia computadorizada por raios X
• ISSN: 1806-3756; 1806-3713; 1806-3756
• DOI: 10.36416/1806-3756/E20200096

Many conditions result in chronic interstitial lung disease (ILD), being classified as fibrosing ILDs, including idiopathic pulmonary fibrosis, connective tissue diseases, sarcoidosis, and fibrotic hypersensitivity pneumonitis. HRCT plays an important role in the clinical evaluation of fibrosing ILDs. Current treatment perspectives are encouraging and reinforce the need for HRCT scans of adequate technical quality for early detection of fibrosing ILD. Despite efforts in this regard, the significance and management of imaging findings of early interstitial lung abnormalities have yet to be clarified. After identification of CT findings consistent with fibrosing ILD, radiologists must be able to identify characteristic morphological patterns and, in some cases, features of specific clinical entities. In cases in which HRCT features are not sufficiently specific for a definitive diagnosis, HRCT can aid in selecting the best site for surgical lung biopsy. CT follow-up is useful for identifying progressive fibrosing ILDs and detecting complications unrelated to the underlying disease, including infections, acute exacerbations, and neoplasms. Automated quantification tools have clinical applicability and are likely to be available for use in imaging analysis in the near future. In addition, incorporation of CT evaluation into scoring systems based on clinical and functional parameters for staging fibrosing disease is likely to become valuable in determining prognosis. Knowledge of the clinical applications of CT evaluation is essential for specialists managing patients with fibrosing ILD and can have a positive impact on the clinical course of the disease.